700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1,543
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Ms. Elaine O'Hara | Executive VP & Chief Strategy Officer | 無 | 無 | 1968 |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
截至 2024年5月1日 止,Novavax, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中:7;董事會:4;股東權利:5;現金賠償:5。